Berry WR - Search Results

1

Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer.

Pond GR, Berry WR, Galsky MD, Wood BA, Leopold L, Sonpavde G. Pond GR, et al. Among authors: berry wr. Clin Genitourin Cancer. 2012 Dec;10(4):239-45. doi: 10.1016/j.clgc.2012.06.004. Epub 2012 Sep 19. Clin Genitourin Cancer. 2012. PMID: 23000202 Clinical Trial.

2

Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years.

Beer TM, Berry W, Wersinger EM, Bland LB. Beer TM, et al. Clin Prostate Cancer. 2003 Dec;2(3):167-72. doi: 10.3816/cgc.2003.n.025. Clin Prostate Cancer. 2003. PMID: 15040860 Clinical Trial.

3

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators. Tannock IF, et al. Among authors: berry wr. N Engl J Med. 2004 Oct 7;351(15):1502-12. doi: 10.1056/NEJMoa040720. N Engl J Med. 2004. PMID: 15470213 Free article. Clinical Trial.

4

Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer.

Berry WR, Hathorn JW, Dakhil SR, Loesch DM, Jackson DV, Gregurich MA, Newcomb-Fernandez JK, Asmar L. Berry WR, et al. Clin Prostate Cancer. 2004 Sep;3(2):104-11. doi: 10.3816/cgc.2004.n.020. Clin Prostate Cancer. 2004. PMID: 15479494 Clinical Trial.

5

Hormone refractory prostate cancer: Management and advances.

Sonpavde G, Hutson TE, Berry WR. Sonpavde G, et al. Among authors: berry wr. Cancer Treat Rev. 2006 Apr;32(2):90-100. doi: 10.1016/j.ctrv.2005.12.005. Epub 2006 Feb 3. Cancer Treat Rev. 2006. PMID: 16458434 Review.

6

Systemic chemotherapy for urothelial cancer.

Sonpavde G, Hutson TE, Berry WR. Sonpavde G, et al. Among authors: berry wr. Clin Genitourin Cancer. 2006 Jun;5(1):34-42. doi: 10.3816/CGC.2006.n.015. Clin Genitourin Cancer. 2006. PMID: 16859577 Review.

7

Problems with the randomized discontinuation design.

Sonpavde G, Hutson TE, Galsky MD, Berry WR. Sonpavde G, et al. Among authors: berry wr. J Clin Oncol. 2006 Oct 1;24(28):4669-70; author reply 4670-1. doi: 10.1200/JCO.2006.08.1026. J Clin Oncol. 2006. PMID: 17008711 No abstract available.

8

A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer.

Berry W, Friedland D, Fleagle J, Jackson D, Ilegbodu D, Boehm KA, Asmar L. Berry W, et al. Clin Genitourin Cancer. 2006 Sep;5(2):131-7. doi: 10.3816/CGC.2006.n.029. Clin Genitourin Cancer. 2006. PMID: 17026801 Clinical Trial.

9

Phase II study of low-dose docetaxel/estramustine in elderly patients or patients aged 18-74 years with hormone-refractory prostate cancer.

Chittoor S, Berry W, Loesch D, Logie K, Fleagle J, Mull S, Boehm KA, Zhan F, Asmar L. Chittoor S, et al. Clin Genitourin Cancer. 2006 Dec;5(3):212-8. doi: 10.3816/CGC.2006.n.039. Clin Genitourin Cancer. 2006. PMID: 17239275 Clinical Trial.

10

Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer.

Sonpavde G, Chi KN, Powles T, Sweeney CJ, Hahn N, Hutson TE, Galsky MD, Berry WR, Kadmon D. Sonpavde G, et al. Among authors: berry wr. Cancer. 2007 Dec 15;110(12):2628-39. doi: 10.1002/cncr.23085. Cancer. 2007. PMID: 17941029 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

140 results

Search Page

Filters